“We’re very excited to have Dr. Jane Barlow be a part of Sera’s gifted board,” mentioned Gregory C. Critchfield, CEO and Chairman of Sera Prognostics. “Jane possesses deep experience in bringing novel services and products to the market, by way of operations, technique improvement and board experiences. Jane’s distinctive background in pioneering quite a lot of novel well being companies will probably be useful to Sera as we obtain Sera’s necessary imaginative and prescient of enhancing the well being of moms and infants and concurrently realizing healthcare price financial savings for society.”
Dr. Barlow has served as Chief Government Officer of Jane Barlow & Associates, LLC, a consulting agency targeted on value-based well being care companies, since January 2017, and Government Vice President and Chief Scientific Officer at Actual Endpoints, a knowledge, analytics, and advisory agency, since January 2017. She at present serves on the board of administrators of ContraFect Corp., a publicly traded biotechnology firm, and Viracta Therapeutics, Inc., a publicly traded precision oncology firm. Dr. Barlow additionally serves on the board of administrators of Level Well being, a healthcare navigation platform, the advisory board of Refactor Well being, and the Biotech Advisory Board of Pictet Asset Administration, an asset administration agency. Previous to her present roles, Dr. Barlow was Affiliate Chief Medical Officer at CVS Well being and Chief Medical Officer of CVS Well being’s Authorities Providers arm the place she efficiently carried out industry-leading medical methods supporting drug buying, distribution, and utilization administration. Previously, she served as Vice President of Scientific Innovation at Medco Well being Options, main the adoption of cutting-edge therapeutic applications by way of all elements of pharmacy. Dr. Barlow beforehand served on the board of administrators of Momenta Prescription drugs, Inc., (previous to and through its sale to Johnson and Johnson), Therapeutics MD Inc., and SilverScript Insurance coverage Firm. Dr. Barlow obtained her medical diploma from Creighton College College of Medication and subsequently accomplished her residency in occupational and environmental medication at The Johns Hopkins College, the place she additionally earned her M.P.H. Moreover, she holds an M.B.A. from the College of Alabama. She is board-certified in occupational medication and a fellow of the American School of Occupational and Environmental Medication and the American School of Preventive Medication. She is a diplomat of the American School of Doctor Executives and a member of the American Medical Affiliation.
“I’m excited to hitch Sera’s board and its give attention to significant and revolutionary options to enhance the well-being of moms and newborns,” mentioned Dr. Jane Barlow. “Sera’s customized method to advancing the well being of pregnant moms and infants is an enabler of improved outcomes and price financial savings that profit moms, infants and payers. I stay up for working with the administration workforce and board as we advance methods to realize these objectives.”
About Sera Prognostics, Inc.
Sera Prognostics is a number one well being diagnostics firm devoted to enhancing the lives of girls and infants by way of precision being pregnant care. Sera’s mission is to ship early, pivotal info in being pregnant to physicians, enabling them to enhance the well being of their sufferers, leading to reductions within the prices of healthcare supply. Sera has a sturdy pipeline of revolutionary diagnostic assessments targeted on the early prediction of preterm beginning threat and different problems of being pregnant. Sera’s precision medication PreTRM® Check studies to a doctor the individualized threat of spontaneous untimely supply in a being pregnant, enabling earlier proactive interventions in girls with greater threat. Sera Prognostics is situated in Salt Lake Metropolis, Utah.
About Preterm Delivery
Preterm beginning is outlined as any beginning earlier than 37 weeks’ gestation and is the main explanation for sickness and demise in newborns. The 2021 March of Dimes Report Card reveals that a couple of in ten infants is born prematurely. Prematurity is related to a considerably elevated threat of main long-term medical problems, together with studying disabilities, cerebral palsy, continual respiratory sickness, mental incapacity, seizures, and imaginative and prescient and listening to loss, and may generate vital prices all through the lives of affected youngsters. The annual well being care prices to handle short- and long-term problems of prematurity in the USA have been estimated to be roughly $25 billion for 2016.
In regards to the PreTRM®
The PreTRM® check is the one broadly validated, commercially out there blood-based biomarker check that gives an early, correct and individualized threat prediction for spontaneous preterm beginning in asymptomatic singleton pregnancies. The PreTRM® check measures and analyzes proteins within the blood which are extremely predictive of preterm beginning. The PreTRM® check permits physicians to establish, throughout the nineteenth or twentieth week of being pregnant, which girls are at elevated threat for preterm beginning, enabling extra knowledgeable, customized medical choices based mostly on every girl’s particular person threat. The PreTRM® check is ordered by a medical skilled.
Sera Prognostics, the Sera Prognostics brand, The Being pregnant Firm, and PreTRM are emblems or registered emblems of Sera Prognostics, Inc. in the USA and/or different nations.
Secure Harbor Assertion
This press launch accommodates “forward-looking statements” inside the which means of the Non-public Securities Litigation Reform Act of 1995, together with statements regarding Dr. Barlow’s appointment serving to to realize the Firm’s imaginative and prescient of enhancing the well being of moms and infants and concurrently realizing healthcare price financial savings for society; and the corporate’s strategic directives below the caption “About Sera Prognostics, Inc.” These “forward-looking statements” are based mostly on administration’s present expectations of future occasions and are topic to various dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these set forth in or implied by forward-looking statements. These dangers and uncertainties embrace, however aren’t restricted to: web losses, money era, and the potential want to lift extra capital; revenues from the PreTRM check representing considerably all Firm revenues so far; the necessity for broad scientific and market acceptance of the PreTRM check; a concentrated variety of materials clients; our means to introduce new merchandise; potential competitors; our proprietary biobank; vital suppliers; the continued COVID-19 pandemic and its impression on our operations, in addition to the enterprise or operations of third events with whom we conduct enterprise; estimates of complete addressable market alternative and forecasts of market development; potential third-party payer protection and reimbursement; new reimbursement methodologies relevant to the PreTRM check, together with new CPT codes and fee charges for these codes; modifications in FDA regulation of laboratory-developed assessments; the mental property rights defending our assessments and market place; and different components mentioned below the heading “Danger Components” contained in our Quarterly Stories on Type 10-Q, Annual Stories on Type 10-Ok, or Present Stories on Type 8-Ok filed with the SEC now and again. All info on this press launch is as of the date of the discharge, and the Firm undertakes no responsibility to replace this info until required by legislation.
SOURCE Sera Prognostics, Inc.